Patents Assigned to GSF-Forschungszentrum fur Umwelt und Gesundheit GmbH
-
Patent number: 9085767Abstract: The present invention relates to a novel class of gene trap vector (enhanced gene trap vectors, eGTV) for efficiently identifying silent or weakly expressed target genes in mammalian genomes, methods of their production and methods for identifying and mutating target genes by using the enhanced gene trap vectors. The gene trap vectors of the present invention can also be used for inducing the expression of silent genes and enhancing the expression of weakly expressed genes. The use of the enhanced gene trap vectors for creating transgenic organisms to identify gene function and to validate pharmaceutical compounds prior to clinical applications is a further aspect of the present invention.Type: GrantFiled: November 28, 2005Date of Patent: July 21, 2015Assignees: FRANKGEN BIOTECHNOLOGIE AG, GSF FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GMBH, MPG MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.Inventors: Harald Von Melchner, Frank Schnütgen, Wolfgang Wurst, Patricia Ruiz
-
Patent number: 8518699Abstract: The invention relates to a modified lymphoid cell having gene conversion fully or partially replaced by hypermutation, wherein said cell has no deleterious mutations in genes encoding paralogues and analogues of the RAD51 protein, and wherein said cell is capable of directed and selective genetic diversification of a target nucleic acid by hypermutation or a combination of hypermutation and gene conversion. The invention also relates to a method for diversifying any transgenic target gene in said cell. Preferably, the target gene is integrated into the immunoglobulin light or heavy chain locus by targeted integration.Type: GrantFiled: February 23, 2005Date of Patent: August 27, 2013Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit, GmbHInventors: Jean-Marie Buerstedde, Hiroshi Arakawa
-
Patent number: 8197825Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: GrantFiled: June 14, 2010Date of Patent: June 12, 2012Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Patent number: 8153138Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: GrantFiled: September 19, 2006Date of Patent: April 10, 2012Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Publication number: 20100266630Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: ApplicationFiled: September 19, 2006Publication date: October 21, 2010Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Publication number: 20100199360Abstract: The present invention relates to a novel class of gene trap vector (enhanced gene trap vectors, eGTV) for efficiently identifying silent or weakly expressed target genes in mammalian genomes, methods of their production and methods for identifying and mutating target genes by using the enhanced gene trap vectors. The gene trap vectors of the present invention can also be used for inducing the expression of silent genes and enhancing the expression of weakly expressed genes. The use of the enhanced gene trap vectors for creating transgenic organisms to identify gene function and to validate pharmaceutical compounds prior to clinical applications is a further aspect of the present invention.Type: ApplicationFiled: November 28, 2005Publication date: August 5, 2010Applicants: FRANKGEN BIOTECHNOLOGIE AG., GSF FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GMBH, MPG MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.Inventors: Harald Von Melchner, Frank Schnutgen, Wolfgang Wurst, Patricia Ruiz
-
Patent number: 7198934Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: GrantFiled: May 15, 2002Date of Patent: April 3, 2007Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Publication number: 20070071769Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: ApplicationFiled: September 19, 2006Publication date: March 29, 2007Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Publication number: 20070071770Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: ApplicationFiled: September 19, 2006Publication date: March 29, 2007Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Patent number: 7183047Abstract: The present invention relates to a reporter gene construct for the detection of the HIV Rev and HIV Tat proteins. Furthermore, the invention relates to a functionality test method for Rev and Rev fusion proteins prepared in a recombinant manner, a method of screening for sequences of different origin for their activity as an instability element, a method of screening for sequences which cause the transport out of the nucleus into the cytoplasm by binding to cellular or other viral shuttle proteins, as well as to a method for the detection of HIV-infected cells. The reporter gene construct according to the present invention, after it has been introduced into cells, in the presence of HIV Rev and HIV Tat proteins results in the formation of reporter proteins which may be used for quantitative/qualitative detection of the HIV Rev and HIV Tat proteins.Type: GrantFiled: June 20, 2002Date of Patent: February 27, 2007Assignee: GSF-Forschungszentrum für Umwelt und Gesundheit, GmbHInventors: Ruth Brack-Werner, Markus Neumann, Horst Wolff, Volker Erfle
-
Patent number: 7126352Abstract: In a method and device for determining the moisture content and conductivity in the ground and in bulk materials, a capacitive sensor is disposed in the ground or the bulk material, the sensor is charged from a constant external voltage supply with a given initial current from a given first voltage threshold value to a given second voltage threshold value and either a voltage/time diagram is determined or a first charging time required for charging the sensor from the first to the second voltage threshold values by the constant external voltage supply is determined and a second charging time is determined wherein either the initial current and/or at least one of the two voltage threshold values are altered and the water content and the conductivity are determined by verification of the two charging times or of the voltage/time diagram.Type: GrantFiled: May 24, 2005Date of Patent: October 24, 2006Assignee: GSF - Forschungszentrum für Umwelt und Gesundheit GmbHInventor: Ruth Bernhard
-
Publication number: 20060154316Abstract: A method for the identification and/or quantification of GBP-1 or fragments of this protein in the culture supernatant of a tissue sample, a body fluid sample or a sample from a cell culture supernatant is described.Type: ApplicationFiled: December 19, 2003Publication date: July 13, 2006Applicant: GSF-Forschungszentrum für Umwelt und Gesundheit GmbHInventors: Michael Sturzl, Clara Lubeseder-Martellato, Eric Guenzi, Elisabeth Kremmer
-
Patent number: 7074389Abstract: The invention describes a means for the treatment of diseases of the tracheo-bronchial tract, particularly of COPD.Type: GrantFiled: September 11, 2002Date of Patent: July 11, 2006Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit, GmbHInventors: Marion Frankenberger, Konrad Maier, Gerhard Scheuch, Hans-Werner Ziegler-Heitbrock
-
Patent number: 7049145Abstract: The present invention relates to mutant MVA vaccinia viruses, which are used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by using the mutant MVA viruses and the DNA-vector constructs. The mutant MVA vaccinia viruses of the present invention are characterized in that the MVA ORF 050L gene or a functional part thereof has been inactivated in the viral genome.Type: GrantFiled: September 11, 2002Date of Patent: May 23, 2006Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit, GmbHInventors: Volker Erfle, Simone Hornemann, Gerd Sutter
-
Patent number: 7018632Abstract: According to the invention there is described a method for ex vivo immunization of humans and animals comprising the following steps: a) isolating autologous tumor cells; b) treating the tumor cells to prevent the survival thereof following reinfusion; c) incubating the thus treated tumor cells with intact heterologous bispecific and/or trispecific antibodies showing the following properties: ?—binding to a T cell; ?—binding to at least one antigen on a tumor cell; ?—binding, by their Fc portion (in the case of bispecific antibodies), or by a third specificity (in the case of trispecific antibodies) to Fc receptor-positive cells.Type: GrantFiled: June 15, 1998Date of Patent: March 28, 2006Assignee: GSF-Forschungszentrum für Umwelt und Gesundheit GmbHInventors: Horst Lindhofer, Hans-Joachim Kolb, Reinhard Zeidler, Georg Bornkamm
-
Patent number: 6893634Abstract: The present invention relates to capsules encapsulating cytochrome P450 producing cells and cytochrome P450 producing retroviral packaging cells. Furthermore, the present invention relates to the treatment of cancer or any other relevant disease with said capsules and to the use of said capsules for the preparation of a pharmaceutical composition for said treatment.Type: GrantFiled: September 24, 1998Date of Patent: May 17, 2005Assignees: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbH, Bavarian Nordic A/SInventors: Walter H. Günzburg, Peter Karle, Robert Saller, Brian Salmons, Matthias Löhr, Peter Müller
-
Publication number: 20040228840Abstract: A new DNA vector is disclosed comprising a nucleic acid sequence useful for inserting heterologous sequences into the genome of poxviruses by homologous recombination. Also disclosed are recombinant poxviruses carrying heterologous coding sequences transferred by the DNA vector.Type: ApplicationFiled: September 23, 2003Publication date: November 18, 2004Applicant: GSF FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GMBHInventors: Stefan Wintersperger, Robert Baier, Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Patent number: 6782845Abstract: IVC rack system comprising a plurality of IVC cages 13 for test animals which are supplied with sterile air, wherein samples of exhaust air from the IVC cages 13 are supplied from sampling points 15 to at least one sentinel cage 24 housing sentinel animals as bio-indicators for the detection of infectious particles within the exhaust air samples, and to at least one particle sampling filter 33 for the identification of pathogens.Type: GrantFiled: July 18, 2003Date of Patent: August 31, 2004Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Jörg Schmidt, Markus Brielmeier
-
Patent number: 6727499Abstract: In a method and apparatus for detecting compounds in a gas stream, the gas stream with the compounds to be detected is conducted into an ionization chamber of a mass spectrometer where the gas stream is subjected in the ion chamber in a pulsed manner alternately to UV laser pulses and to vacuum ultraviolet VUV laser pulses and the ions generated thereby are directed into the mass spectrometer for detection therein to determine the compounds in the gas stream.Type: GrantFiled: September 14, 2002Date of Patent: April 27, 2004Assignee: GSF-Forschungszentrum für Umwelt und Gesundheit GmbHInventors: Ralf Zimmermann, Jorg Heger, Antonius Kettrup, Fabian Mühlberger, Klaus Hafner, Ulrich Boesl
-
Patent number: 6681762Abstract: A device for flow rate limitation at low differential pressures, particularly for limiting the volumetric inhalation flow during inhalation of therapeutic aerosols, consists of a housing 11 including an aspiration orifice 14, an inhalation orifice 15 and a flow passage 23 disposed therebetween. The flow passage has a flat elongate cross-section with flexible large-area walls 18, 20 having a cross-sectional area adapted to be reduced, as a function of the differential pressure prevailing between the inhalation orifice and the aspiration orifice, as well as of the flexibility of the material of the walls, to a size appropriate for a predetermined volumetric maximum inhalation flow.Type: GrantFiled: March 16, 2000Date of Patent: January 27, 2004Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Gerhard Scheuch, Knut Sommerer, Bernhard Müllinger, Friedel Haas, Sascha Roeder